Skip to main navigation

Back to SpringWorksTx.com
Investors & Media
Contact Us
Linkedin
Twitter

Overview
News & Events
- Press Releases
- Events & Presentations
Corporate Governance
Financial Information
- SEC Filings
- Annual Reports
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Investor Resources
Investors + Media
Medical Professionals
Contact Us
Linkedin
Twitter

Press Releases

Items Per Page

Year

30 Aug 2019

SpringWorks Therapeutics Appoints Alan Fuhrman to Its Board of Directors

PDF Version

29 Aug 2019

SpringWorks Therapeutics Receives Breakthrough Therapy Designation for Nirogacestat for the Treatment of Adult Patients with Progressive, Unresectable, Recurrent or Refractory Desmoid Tumors

PDF Version

15 Aug 2019

SpringWorks Therapeutics Announces Appointment of Frank Perier as Chief Financial Officer

PDF Version

30 Jul 2019

European Commission Grants Orphan Drug Designation for SpringWorks Therapeutics’ MEK Inhibitor, Mirdametinib, for the Treatment of Neurofibromatosis Type 1

PDF Version

27 Jun 2019

SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma

PDF Version

18 Jun 2019

BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

PDF Version

03 Jun 2019

SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1

PDF Version

20 May 2019

SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid Tumors

PDF Version

06 May 2019

SpringWorks Therapeutics Announces Initiation of Phase 1b Clinical Trial of MEK Inhibitor PD-0325901 in Combination with BeiGene’s RAF Dimer Inhibitor Lifirafenib in Advanced or Refractory Solid Tumors

PDF Version

01 Apr 2019

SpringWorks Therapeutics Completes $125 Million Series B Financing

PDF Version

Pagination

First page
Previous page
…
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Current page 15
Page 16
Next page
Last page

Displaying 141 - 150 of 159

Springworks - Toolkits

Print Page
Email Alerts
RSS Feeds
Investor Contacts

Request E-mail Alerts

Social Links

Footer 1

Who We Are
Focus Areas

Footer 2

Pipeline
Careers
- View Opportunities

Footer 3

Patients
Contact

Footer 4

Investors & Media

© 2025 SpringWorks Therapeutics. All rights reserved.

Copyright Links

Privacy Policy
Terms of Use
Cookie Policy